CN102958920A - 用于治疗红斑痤疮的甲硝唑酯 - Google Patents

用于治疗红斑痤疮的甲硝唑酯 Download PDF

Info

Publication number
CN102958920A
CN102958920A CN2011800324626A CN201180032462A CN102958920A CN 102958920 A CN102958920 A CN 102958920A CN 2011800324626 A CN2011800324626 A CN 2011800324626A CN 201180032462 A CN201180032462 A CN 201180032462A CN 102958920 A CN102958920 A CN 102958920A
Authority
CN
China
Prior art keywords
acid
formula
compounds
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800324626A
Other languages
English (en)
Chinese (zh)
Inventor
J-G.布瓦托
J-M.兰热
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Publication of CN102958920A publication Critical patent/CN102958920A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2011800324626A 2010-06-29 2011-06-29 用于治疗红斑痤疮的甲硝唑酯 Pending CN102958920A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1055241 2010-06-29
FR1055241A FR2961809B1 (fr) 2010-06-29 2010-06-29 Esters de metronidazole pour traiter la rosacee
PCT/EP2011/060923 WO2012001053A1 (en) 2010-06-29 2011-06-29 Metronidazole esters for treating rosacea

Publications (1)

Publication Number Publication Date
CN102958920A true CN102958920A (zh) 2013-03-06

Family

ID=42790955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800324626A Pending CN102958920A (zh) 2010-06-29 2011-06-29 用于治疗红斑痤疮的甲硝唑酯

Country Status (23)

Country Link
US (1) US8802710B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2588462B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2013529667A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20130088135A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102958920A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR081783A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2011273498A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012032490A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2801977A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1115622T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2588462T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2518119T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2961809B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20140966T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2013CN00515A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2012014632A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2588462T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2588462E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS53623B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2013103693A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2588462T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (1) SMT201400174B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2012001053A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025152340A1 (zh) * 2024-01-15 2025-07-24 中国药科大学 一种甲硝唑衍生物、制备方法及在药物制备中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9715942B2 (en) 2015-06-09 2017-07-25 International Business Machines Corporation Built-in self-test (BIST) circuit and associated BIST method for embedded memories

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074290A2 (en) * 2001-03-15 2002-09-26 Agis Industries (1983) Ltd. Dermatological preparations containing a nsaid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127274A3 (en) * 1983-03-25 1987-05-20 The Upjohn Company Esters of metronidazole and compositions containing them
US8853247B2 (en) * 2007-11-02 2014-10-07 Nektar Therapeutics Oligomer-nitroimidazole anti-infective conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074290A2 (en) * 2001-03-15 2002-09-26 Agis Industries (1983) Ltd. Dermatological preparations containing a nsaid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HC KORTING ET AL.: "Current topical and systemic approaches to treatment of rosacea", 《JEADV》 *
SONAL DUBEY ET AL.: "Evaluation of lipophilicity, antimicrobial activity and mutagenicity of some novel ester prodrugs of metronidazole", 《INDIAN JOURNAL OF CHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025152340A1 (zh) * 2024-01-15 2025-07-24 中国药科大学 一种甲硝唑衍生物、制备方法及在药物制备中的应用

Also Published As

Publication number Publication date
JP2013529667A (ja) 2013-07-22
RU2013103693A (ru) 2014-08-10
MX2012014632A (es) 2013-02-07
WO2012001053A1 (en) 2012-01-05
BR112012032490A2 (pt) 2016-12-13
KR20130088135A (ko) 2013-08-07
FR2961809B1 (fr) 2012-07-06
US20130217740A1 (en) 2013-08-22
HRP20140966T1 (hr) 2015-01-02
SMT201400174B (it) 2015-01-15
FR2961809A1 (fr) 2011-12-30
EP2588462A1 (en) 2013-05-08
PL2588462T3 (pl) 2015-03-31
CA2801977A1 (en) 2012-01-05
IN2013CN00515A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-03
DK2588462T3 (da) 2014-11-03
EP2588462B1 (en) 2014-08-13
US8802710B2 (en) 2014-08-12
ES2518119T3 (es) 2014-11-04
AU2011273498A1 (en) 2013-01-10
PT2588462E (pt) 2014-10-30
CY1115622T1 (el) 2017-01-04
SI2588462T1 (sl) 2015-02-27
RS53623B1 (en) 2015-04-30
AR081783A1 (es) 2012-10-17

Similar Documents

Publication Publication Date Title
US11547681B2 (en) N-acylethanolamide derivatives and uses thereof
EP2588463B1 (en) Metronidazole esters for treating rosacea
KR20120115380A (ko) 마이봄선 기능 장애의 치료 방법
EP3851101A1 (en) Ultrapure tetrahydrocannabinol-11-oic acids
CA2458131A1 (en) Jnk activation inhibitor
CN102958920A (zh) 用于治疗红斑痤疮的甲硝唑酯
US8796325B2 (en) Metronidazole esters for treating rosacea
JP2006509038A (ja) 医薬組成物用の高エナンチオマー純度を有するデキサナビノール
WO2020135560A1 (zh) 乙酰水杨酸衍生物及其应用
CN104220083B (zh) 用于治疗动脉硬化性血管疾病的方法和组合物
CN117242076A (zh) 基于噻吩的化合物及其作为bckdk抑制剂的用途
US20220112152A1 (en) Triphenylphosphonium-tethered salicylamine derivatives
US20210220336A1 (en) Topical detomidine formulations
EP4532481A1 (en) Mutual prodrugs of cromoglicic acid
CN120091816A (zh) 伐尼克兰相关的化合物以及用于治疗包括烟草使用障碍的疾病和状况的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20130306

C20 Patent right or utility model deemed to be abandoned or is abandoned